Amplify Cybersecurity ETF vs Pfizer Inc — how do they compare? Amplify Cybersecurity ETF trades at $108, while Pfizer Inc trades at $24.89 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while Amplify Cybersecurity ETF pays none, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| HACK | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $114.29 | $28.56 |
52-Week Low | $70.69 | $23.29 |
Market Cap | — | $141.06B |
Volume | — | 29,869,932 |
Enterprise Value | — | $191.72B |
Dividend Yield | — | 6.95% |
Signals from Pluang's Aura AI — not financial advice
HACK trades at $110.08, down 0.86% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX above 60). The ETF benefits from rising cybersecurity spending, which surpassed $300 billion in 2026 (24/7 Wall Street, 2026-07-03), and recently hit a 52-week high (Zacks Investment Research, 2026-05-26). Institutional interest is growing, with D.A. Davidson increasing its stake by 44.8% in Q1 2026 (Defense World, 2026-07-19).
Outlook remains positive due to structural demand for cybersecurity, but risks include sector volatility and reliance on tech spending. The ETF offers exposure to a high-growth theme, yet investors face concentration in tech and sensitivity to corporate budget cycles. Near-term resistance is at $111, with support at $110.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Trailing returns across standard periods
Latest headlines on both assets
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →